Iris pigmentation changes monitored with glaucoma therapy

Uppsala, Sweden—Adjunctive latanoprost (Xalatan, Pfizer) therapy for open-angle glaucoma is safe and effective, based on the results of a 5-year assessment of the drug. The mean decrease in IOP was 25% of the baseline IOP and this was sustained without any treatment change in 70% of eyes.

Related Videos
Related Content

FDA-approved drug shows promise in laboratory models for Leber congenital amaurosis type 10

April 2nd 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Prevent Blindness designates April as women’s eye health and safety month

April 1st 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Nanoscope Therapeutics announces positive topline results from Phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa

March 31st 2023

Recipe for disaster? Starting out in ophthalmology during the pandemic

March 31st 2023

FDA-approved drug shows promise in laboratory models for Leber congenital amaurosis type 10

April 2nd 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Prevent Blindness designates April as women’s eye health and safety month

April 1st 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Nanoscope Therapeutics announces positive topline results from Phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa

March 31st 2023

Recipe for disaster? Starting out in ophthalmology during the pandemic

March 31st 2023

FDA-approved drug shows promise in laboratory models for Leber congenital amaurosis type 10

April 2nd 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Prevent Blindness designates April as women’s eye health and safety month

April 1st 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Nanoscope Therapeutics announces positive topline results from Phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa

March 31st 2023

Recipe for disaster? Starting out in ophthalmology during the pandemic

March 31st 2023
© 2023 MJH Life Sciences

All rights reserved.